Potential Global Impact of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure.
Khawaja M TalhaJaved ButlerStephen J GreeneRahul AggarwalStefan D AnkerBrian L ClaggettKieran F DochertyScott D SolomonJohn J V McMurrayJames L JanuzziMuthiah VaduganathanGregg C FonarowPublished in: European journal of heart failure (2023)
Optimal implementation of SGLT-2 inhibitors globally in HF is projected to prevent approximately 7-8 million worsening HF events and cardiovascular deaths over 3 years. This article is protected by copyright. All rights reserved.